| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
Revenue  | 3,160 | 3,874 | 4,139 | 4,005 | 5,102 | 5,584 | 7,032 | 9,074 | 8,112 | 8,184 | 9,424 |
| Expenses | 1,950 | 2,359 | 2,618 | 2,630 | 3,074 | 3,572 | 4,110 | 5,078 | 5,399 | 5,640 | 6,266 |
| EBITDA | 1,210 | 1,515 | 1,521 | 1,375 | 2,028 | 2,012 | 2,923 | 3,996 | 2,713 | 2,544 | 3,158 |
| Operating Profit % | 37 % | 38 % | 36 % | 32 % | 38 % | 34 % | 41 % | 43 % | 30 % | 28 % | 31 % |
| Depreciation | 136 | 118 | 123 | 143 | 169 | 186 | 256 | 312 | 343 | 378 | 390 |
| Interest | 2 | 4 | 2 | 1 | 4 | 6 | 1 | 1 | 1 | 3 | 3 |
| Profit Before Tax | 1,072 | 1,393 | 1,395 | 1,231 | 1,855 | 1,820 | 2,666 | 3,684 | 2,369 | 2,163 | 2,765 |
| Tax | 221 | 267 | 335 | 354 | 502 | 443 | 682 | 723 | 545 | 563 | 698 |
| Net Profit | 852 | 1,126 | 1,060 | 877 | 1,353 | 1,377 | 1,984 | 2,961 | 1,824 | 1,600 | 2,067 |
| EPS in ₹ | 32.08 | 42.41 | 39.95 | 33.04 | 50.96 | 51.85 | 74.75 | 111.52 | 68.69 | 60.27 | 77.80 |
Divis Laboratories
6,123.50
+27.25
(0.45%)
Market Cap
1,62,559.68
Eps
60.27
PE Ratio (TTM)
78.25
Dividend Yield
0.49
Industry
Healthcare
52 Week High
6,285.45
52 Week low
3,350.00
PB Ratio
11.79
Debt to Equity
0.00
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Divi's Laboratories: Analyst Predicts 30% Downside Despite Strong Q3 Results1 day ago
Elara Securities maintains a 'sell' rating on Divi's Laboratories with a price target of ₹4,098, implying a 30% downside. Despite Q3 revenue growth of 25% and profit increase of 65%, Elara cites concerns over valuation and future growth prospects. The firm expects growth rates to normalize and sees limited margin expansion potential. Conversely, Citi remains bullish, rating Divi's as a top pick with a ₹6,850 target.
Divi's Labs Developing New Gadolinium Compounds1 day ago
Divi's Laboratories is collaborating with innovators to develop new gadolinium compounds. These compounds are currently at various stages of development, as revealed during a company conference call.
Divi's Labs Expects Growth from Generic Portfolio Expansion1 day ago
Divi's Laboratories is anticipating significant growth driven by additions to its generic drug portfolio. The company is strategically positioning itself to capitalize on upcoming patent expirations in the pharmaceutical industry. This expansion of their generic offerings is expected to be a key factor in the company's future revenue and market position.
View more
Growth Rate
Revenue Growth
0.89 %
Net Income Growth
-12.28 %
Cash Flow Change
-48.72 %
ROE
-17.49 %
ROCE
-14.12 %
EBITDA Margin (Avg.)
-7.03 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 4,411 | 4,902 | 6,159 | 6,786 | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 |
| Fixed Assets | 1,309 | 1,439 | 1,559 | 1,996 | 2,088 | 2,782 | 3,704 | 4,325 | 4,722 | 4,739 |
| Current Assets | 2,772 | 3,027 | 4,011 | 4,535 | 4,650 | 4,680 | 6,175 | 8,352 | 9,312 | 9,675 |
| Capital Work in Progress | 218 | 264 | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 778 |
| Investments | 733 | 803 | 1,631 | 1,889 | 1,946 | 971 | 0 | 72 | 77 | 82 |
| Other Assets | 2,151 | 2,397 | 2,525 | 2,781 | 3,513 | 3,863 | 6,360 | 8,508 | 9,428 | 9,871 |
| Total Liabilities | 4,411 | 4,902 | 6,159 | 6,786 | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 |
| Current Liabilities | 776 | 520 | 660 | 653 | 847 | 927 | 1,113 | 1,196 | 1,101 | 1,278 |
| Non Current Liabilities | 141 | 89 | 142 | 208 | 234 | 299 | 367 | 451 | 571 | 621 |
| Total Equity | 3,495 | 4,293 | 5,357 | 5,925 | 6,957 | 7,310 | 9,295 | 11,728 | 12,767 | 13,571 |
| Reserve & Surplus | 3,469 | 4,240 | 5,304 | 5,872 | 6,904 | 7,257 | 9,242 | 11,675 | 12,714 | 13,518 |
| Share Capital | 27 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 3 | 0 | 13 | -17 | 23 | 41 | 1,987 | -816 | -1,045 | 193 |
| Investing Activities | -521 | -406 | -1,140 | -478 | -685 | -84 | 75 | -2,195 | -2,707 | -269 |
| Operating Activities | 826 | 1,038 | 1,150 | 776 | 954 | 1,216 | 1,947 | 1,912 | 2,459 | 1,261 |
| Financing Activities | -303 | -631 | 2 | -314 | -246 | -1,091 | -35 | -532 | -797 | -799 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 51.95 % | 51.95 % | 51.95 % | 51.95 % | 51.94 % | 51.94 % | 51.94 % | 51.94 % | 51.94 % | 51.93 % | 51.93 % | 51.92 % | 51.92 % | 51.90 % | 51.89 % | 51.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.86 % | 14.68 % | 16.16 % | 17.25 % | 17.99 % |
| DIIs | 12.64 % | 12.61 % | 12.64 % | 13.40 % | 13.73 % | 13.93 % | 19.54 % | 20.67 % | 21.07 % | 21.23 % | 20.97 % | 21.88 % | 22.21 % | 21.77 % | 21.06 % | 20.54 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 9.28 % | 8.81 % | 8.87 % | 9.01 % | 9.27 % | 9.53 % | 9.20 % | 9.53 % | 9.61 % | 9.28 % | 9.02 % | 8.85 % | 8.69 % | 7.77 % | 7.41 % | 7.32 % |
| No of Share Holders | 2,08,203 | 1,93,883 | 2,23,403 | 2,74,505 | 3,09,397 | 3,46,905 | 3,79,257 | 4,14,847 | 4,33,621 | 4,02,155 | 3,73,860 | 3,54,482 | 3,47,629 | 2,98,310 | 2,78,899 | 2,80,601 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 10 | 10 | 16 | 16 | 20 | 30 | 0.00 | 30 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.92 | 0.59 | 0.8 | 0.44 | 0.45 | 1.06 | 0.00 | 0.49 | 0.00 |
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,752.75 | 4,20,543.44 | 35.94 | 49,887.20 | 12.06 | 9,648 | 13.77 | 44.79 | |
| 6,123.50 | 1,62,559.68 | 78.25 | 8,184.00 | 0.89 | 1,600 | 64.53 | 60.08 | |
| 1,436.80 | 1,16,037.99 | 23.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 46.67 | |
| 3,114.70 | 1,05,415.60 | 56.43 | 10,785.70 | 11.59 | 1,656 | 13.54 | 35.94 | |
| 2,483.00 | 1,02,440.36 | 51.56 | 10,615.60 | 19.57 | 1,942 | -16.38 | 42.73 | |
| 1,227.55 | 1,02,428.11 | 18.95 | 28,905.40 | 12.36 | 5,578 | 1.69 | 41.25 | |
| 2,185.10 | 99,683.73 | 36.66 | 20,141.50 | 19.94 | 1,936 | 73.53 | 56.12 | |
| 977.00 | 98,309.06 | 22.90 | 19,831.50 | 13.82 | 3,831 | 29.92 | 51.89 | |
| 1,191.75 | 69,217.03 | 18.82 | 29,559.20 | 17.55 | 3,169 | 8.66 | 48.98 | |
| 5,117.95 | 61,192.77 | 28.08 | 12,978.40 | 9.84 | 1,812 | 14.16 | 43.89 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Technical Indicators
RSI(14)
Neutral 59.36
ATR(14)
Less Volatile 209.76
STOCH(9,6)
Neutral 65.20
STOCH RSI(14)
Overbought 98.42
MACD(12,26)
Bullish 43.37
ADX(14)
Weak Trend 17.48
UO(9)
Bearish 61.12
ROC(12)
Uptrend And Accelerating 4.77
WillR(14)
Overbought -15.23
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
